Table 3.

Phenotype analysis of CD19 CAR-T cells infusion products of ALL and NHL patients

	ALL (n=12)	NHL (n=12)	P value
T cell subpopulations
CD8+	59±15.6	55.6±20.3	0.652
CD4+	41±15.5	44.4±20.3	0.649
γδ T cells	1.0±0.8	0.6±1.1	0.140
Differentiation status
TN	60.5±17.3	41.2±22.4	0.027
TCM	15.8±11.8	27.2±14.8	0.048
TEM	12.3±12.1	22.4±13.8	0.072
TEMRA	11.4±5.8	9.2±6.4	0.399
Co-stimulatory / co-inhibitory molecules
CD28 + CD3+	49.5±26.7	44.9±24.5	0.663
CD28 + CD8+	37±19.5	29±14.5	0.267
CD28 + CD4+	12.5±16	15.9±16.7	0.619
PD1 + CD3+	30.3±13.4	34.5±9.7	0.382
PD1 + CD8+	8.8±3.9	10.9±5.3	0.270
PD1 + CD4+	21.5±12.3	23.6±10.2	0.652
LAG3 + CD3+	26.5±11.3	35.5±13	0.082
LAG3 + CD8+	19.8±11	25.9±13.4	0.243
LAG3 + CD4+	6.6±2.5	9.7±5.5	0.097
TIM3 + CD3+	65.8±14.8	60.9±12.7	0.394
TIM3 + CD8+	33.1±11.9	28.8±8.9	0.327
TIM3 + CD4+	32.7±14.4	32.1±15.3	0.925
Chemokine receptors
CCR2 + CD3+	50.7±14.9	50.5±15.9	0.982
CCR2 + CD8+	31.7±14.1	32.2±22.7	0.957
CCR2 + CD4+	18.9±12.7	18.4±12.7	0.915
CCR5 + CD3+	10.5±8.8	16±15.9	0.303
CCR5 + CD8+	2.9±3.7	6.1±8.2	0.233
CCR5 + CD4+	7.6±5.4	10±9.5	0.464
CCR4 + CD3+	33.6±17.2	36.1±11.5	0.682
CCR4 + CD8+	14.5±10.1	15.9±12.7	0.763
CCR4 + CD4+	19.1±13.4	20.1±11.4	0.838
CXCR2 + CD3+	17.7±9.8	15.5±5.4	0.499
CXCR2 + CD8+	4.6±7.5	3.8±3.5	0.743
CXCR2 + CD4+	13.1±8.2	11.6±5.2	0.618
CXCR3 + CD3+	87.4±8.2	79.1±11.1	0.047
CXCR3 + CD8+	52.6±14.9	48.3±21.6	0.580
CXCR3 + CD4+	34.9±13.4	30.8±12.6	0.448

Cells were gated on CD3+F(ab)₂+ CAR-T cells. TN (naïve T cells), CD3+CD45RA+CCR7+; TCM (central memory T cells), CD3+CD45RA−CCR7+; TEM (effector memory T cells), CD3+CD45RA−CCR7−; TEMRA (T cells effector), CD3+CD45RA+CCR7−.

ALL, acute lymphoblastic leukemia; CAR-T, chimeric antigen receptor T cells; NHL, non-Hodgkin's lymphoma.